Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | LPL | P06858 | 10/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746946 | 0.87 | FFAR1 (0.53) | FFAR1LPLLIPGCA1CA2 | |
| SCHEMBL14788157 | 0.86 | FFAR1 (0.58) | FFAR1LPLLIPGCA1CA2 | |
| SCHEMBL24609489 | 0.84 | FFAR1 (0.57) | FFAR1LPLLIPGCA1CA2 | |
| SCHEMBL253540 | 0.84 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL1855038 | 0.82 | FFAR1 (0.55) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL790905 | 0.81 | FFAR1 (0.65) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL3405330 | 0.81 | FFAR1 (0.57) | FFAR1LPLLIPGCA1CA2 | |
| SCHEMBL98872 | 0.81 | FFAR1 (0.53) | FFAR1LPLLIPGCA1CA2 | |
| SCHEMBL15885101 | 0.81 | FFAR1 (0.53) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL20026953 | 0.81 | FFAR1 (0.60) | FFAR1LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024217587-A1 | SUBSTITUTED PYRAZINE COMPOUND HAVING AXL INHIBITORY ACTIVITY | 南京正大天晴制药有限公司 | 2024-10-24 | — | — | WO | disclosed |
| EP-2563789-B1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| EP-2563789-B1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| EP-2496557-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | SYK, BTK, LYN | FFAR1 2864/4885LPL 2461/4885LIPG 924/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | FFAR1 3123/4885LPL 3466/4885LIPG 3163/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | FFAR1 4604/4885LPL 4016/4885LIPG 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.